Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sapitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 14/20 | 0.92 |
| ▸ | EGFR known ✓ | P00533 | 8/20 | 0.92 |
| ▸ | ERBB3 known ✓ | P21860 | 1/20 | 0.92 |
| ▸ | GAK | O14976 | 1/20 | 0.92 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.92 |
| ▸ | LYN | P07948 | 1/20 | 0.92 |
| ▸ | RET | P07949 | 1/20 | 0.92 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.92 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.92 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.92 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.92 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.92 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.92 |
| ▸ | ADK | P55263 | 1/20 | 0.92 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.92 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sapitinib SCHEMBL201895 | 1.00 | ERBB2 (0.92) | ERBB2EGFRGAKRIPK2LYN | |
| Sapitinib SCHEMBL29728247 | 0.96 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| Sapitinib SCHEMBL30362790 | 0.96 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| Sapitinib SCHEMBL202358 | 0.96 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL29731571 | 0.90 | ERBB2 (0.87) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL4884254 | 0.90 | ERBB2 (0.87) | ERBB2EGFRGAKRIPK2LYN | |
| Hydrochloric Acid SCHEMBL4878789 | 0.89 | ERBB2 (0.86) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL4883773 | 0.89 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL29781246 | 0.89 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL3129641 | 0.88 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | claimed |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | claimed |
| US-8088782-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | claimed |
| EP-2303276-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | claimed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | claimed |
| WO-2009138779-A1 | COMBINATION COMPRISING 4- (3-CHLORO-2-FLUOROANILINO) -7-METH0XY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXYJQUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | claimed |
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| CN-102088979-B | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin-4-yl] oxy}quinazoline | ASTRAZENECA AB | 2013-10-16 | — | — | CN | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-20120108814-A1 | PROCESS 738 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| EP-2421827-A2 | PROCESS FOR THE PREPARATION OF 4-(3-CHLORO-2-FLUORO- ANILINO)-7-METHOXY-6- { [1-(N-METHYLCARBAMOYLMETHYL)- PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2012-02-29 | — | — | EP | disclosed |
| US-8088782-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| CN-102088979-A | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin-4-yl] oxy}quinazoline | ASTRAZENECA AB | 2011-06-08 | — | — | CN | disclosed |
| EP-2303276-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010122340-A2 | PROCESS 738 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286982-A1 | NOVEL SALT-554 | KRAS, NISCH, WASHC4 | ERBB2 3185/4885EGFR 2696/4885ERBB3 4034/4885 |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | CDK7, CCNC, CDC73 | ERBB2 2433/4885EGFR 3132/4885ERBB3 3926/4885 |
| US-20120108814-A1 | PROCESS 738 | CYP2C8, CYP4F8, UGT1A8 | ERBB2 2741/4885EGFR 3512/4885ERBB3 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.